Last reviewed · How we verify
Cladribine and pegylated interpheron alpha-2a
Cladribine and pegylated interpheron alpha-2a is a Small molecule drug developed by Hospital Virgen de la Salud. It is currently in Phase 2 development.
At a glance
| Generic name | Cladribine and pegylated interpheron alpha-2a |
|---|---|
| Sponsor | Hospital Virgen de la Salud |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cladribine and pegylated interpheron alpha-2a CI brief — competitive landscape report
- Cladribine and pegylated interpheron alpha-2a updates RSS · CI watch RSS
- Hospital Virgen de la Salud portfolio CI
Frequently asked questions about Cladribine and pegylated interpheron alpha-2a
What is Cladribine and pegylated interpheron alpha-2a?
Cladribine and pegylated interpheron alpha-2a is a Small molecule drug developed by Hospital Virgen de la Salud.
Who makes Cladribine and pegylated interpheron alpha-2a?
Cladribine and pegylated interpheron alpha-2a is developed by Hospital Virgen de la Salud (see full Hospital Virgen de la Salud pipeline at /company/hospital-virgen-de-la-salud).
What development phase is Cladribine and pegylated interpheron alpha-2a in?
Cladribine and pegylated interpheron alpha-2a is in Phase 2.